Amyris & CJ CheilJedang Corporation Creating Manufacturing and Sales Partnership

EMERYVILLE, Calif., May 20, 2016 (GLOBE NEWSWIRE) — Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, and South Korea-based CJ CheilJedang Corporation (“CJ”)(KRX:097950), today announced that the companies have signed a Memorandum of Understanding (MOU) to support large-scale manufacturing of Amyris’s farnesene in existing CJ facilities. The arrangement described in the MOU would enable Amyris to utilize CJ’s state of the art manufacturing capacity while minimizing the capital investment necessary to support projected near- and mid-term demand for product applications using farnesene. The partnership is also expected to include the opportunity for CJ Bio (division of CJ CheilJedang) to market select Amyris products in Asian markets as well as the potential for Amyris to develop several products for CJ Bio. The companies are targeting completing a definitive agreement by the first week of August 2016. “We are very pleased with the innovative approach of CJ CheilJedang, to support quickly ramping up our farnesene capacity with minimal capital investment and with the collaborative partnership to market some of our products in Asia,” said John Melo, President & CEO of Amyris. “This partnership completes our commercialization strategy by providing us the ability to meet our farnesene demand from our current partners without new investment from Amyris and underpins our expected capacity needs to meet farnesene demand that would require building 3-4 new plants the size of our Brotas facility by 2020. We are also pleased with the opportunity to partner with CJ for sales efforts in Asia and the potential to collaborate on new products that meet the needs of their existing customers.” “We are excited to partner with Amyris and leverage... read more

Amyris to Participate in Upcoming Investor Conferences in May 2016

EMERYVILLE, Calif., May 11, 2016 (GLOBE NEWSWIRE) — Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it plans to participate in the following upcoming investor conferences in May 2016. Oppenheimer Emerging Growth ConferenceMay 17, 2016Sofitel Hotel, New York City Naseba Investors ConferenceMay 24, 2016Dubai, United Arab Emirates During each of these events management will meet with new investors in one-on-one only meetings.  Due to the format of these events, no webcast will be available. About Amyris Amyris is the integrated renewable products company that’s enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com. Amyris and the Amyris logo are registered trademarks of Amyris, Inc. Contact: Peter DeNardo Director, Investor Relations and Corporate Communications Amyris, Inc. +1 (510) 740-7481 investor@amyris.com... read more

Amyris First Quarter 2016 Results Deliver Strong Renewable Product Sales Growth and Continued Reduction in Operating Expenses

  Q1 2016 revenues of $8.8 million, including product sales growth of 50% over Q1 2015 Reduced selling, general and administrative expenses by 15% and continued progress in exit from non-strategic activities Agreed on $40 million of financing year to date with existing investors On track to execute 2016 business plan with expected non-GAAP revenue of $90-$105 million for the year from collaborations and expanded product sales agreements with strategic partners EMERYVILLE, Calif., May 10, 2016 (GLOBE NEWSWIRE) — Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced financial results for the first quarter ended March 31, 2016. “The financing announced today in our SEC filings, along with proceeds from our previously announced plan for strategic asset divestments and other cash generating activities, provides us the capital to support our business plan for the year,” said John Melo, Amyris President & CEO. “We are successfully expanding our collaboration portfolio, executing on several significant farnesene supply agreements for disruptive applications for our partners, and growing our overall sales of high-value, No Compromise® ingredients. While we still have work to do, we believe we are currently on track to deliver on our goal of becoming a self-sustaining business by the end of this year.” Continued Melo, “We thank our investors, including the Bill & Melinda Gates Foundation, for their continued strong financial support in helping our company to deliver on its mission to make renewable products mainstream while saving lives and reducing the impact of a growing population on our planet’s resources.” Key Highlights Other key operating and development highlights during the first quarter and more recently included: Signed five-year Biofene®... read more

Biossance™ Announces the Blacklist ─ 2,000+ Potentially Harmful Cosmetic Ingredients it Refuses to Use while Delivering Products Consumers Love to Use

  EMERYVILLE, Calif., May 06, 2016 (GLOBE NEWSWIRE) — Biossance™, the pioneer of sustainable solutions in beauty from Amyris, Inc. (Nasdaq:AMRS), announced today the Blacklist ─ 2,000+ common cosmetic ingredients it refuses to use due to safety and environmental concerns. The regulatory environment in the U.S. affords cosmetic brands the opportunity to use potentially harmful ingredients in cosmetic products. Biossance has created higher standards by adopting rigorous ingredient selection guidelines and omitting ingredients that are potentially harmful to you or the planet. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/b1c11e3f-aa69-4a1a-a3b5-7f3aafc8553b Since its inception, the brand has delivered significant growth while doing the right thing for consumers. This has enabled consumers to select effective products while avoiding using petroleum-based or other ingredients that are potentially harmful to their skin and our planet. No Compromise ─ Only the Good, None of the Bad Beginning with a list of 1,300+ ingredients banned in Europe, Biossance’s Blacklist now totals over 2,000 restricted ingredients, including conflict minerals, parabens and oxybenzone (used in products such as sunscreen and linked to mass die-offs in coral). The result is high-performing products for the skin that are: Results driven Non-toxic Safe for you and the planet Formulated without synthetic fragrances, parabens, phthalates, or mineral oil Ideal for all skin types Dermatologist and ophthalmologist tested “Currently, the U.S. has low standards for ingredients formulated into beauty products and we have the opportunity to set the bar higher and also to continue demonstrating that our brand can do well by doing good,” said Caroline Hadfield, Amyris’s Senior Vice President, Personal Care. “We don’t accept the status quo. We are... read more

Amyris to Announce First Quarter Financial Results on Tuesday, May 10, 2016

EMERYVILLE, Calif., April 29, 2016 (GLOBE NEWSWIRE) — Amyris, Inc. (Nasdaq:AMRS) will report financial results for the first quarter ended March 31, 2016 after market close on Tuesday, May 10, 2016. The Company will hold its quarterly conference call to discuss these results, as well as provide an update on the Company’s business and outlook, at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, May 10, 2016. Conference Call: Tuesday, May 10, 2016, 4:30 p.m. ET/1:30 p.m. PT Dial-in Number: (866) 516-3867 (U.S. & International)Access Code: 95543377 Audio Webcast: A live webcast of the call will be available online on the Amyris website. To listen via live webcast, please visit: http://investors.amyris.com. A replay of the webcast will be available on the Investor Relations section of the Company’s website approximately two hours after the conclusion of the call. About Amyris Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com. Amyris and the Amyris logo are registered trademarks of Amyris, Inc. Contact: Peter DeNardo Director, Investor Relations and Corporate Communications Amyris, Inc. +1 (510) 740-7481 investor@amyris.com... read more

Amyris Signs Five Year Biofene® Supply Agreement with leading Global Nutraceuticals Company with Over $100 Million of Expected Value

Provides Secure Supply for Highly Disruptive Nutraceutical Product   EMERYVILLE, Calif., April 27, 2016 (GLOBE NEWSWIRE) — Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it has executed a five year Biofene® supply agreement with a global nutraceuticals company. This new, long-term agreement replaces the parties’ one-year purchase agreement, which was previously announced on January 4, 2016. Under the new supply agreement, the customer has agreed to a larger Biofene purchase in 2016 with an expected revenue contribution of approximately $9 million and to minimum annual purchase commitments in each of the remaining years of the agreement. In addition, under the new agreement, Amyris is entitled to a quarterly value-share arrangement on the sales of the customer’s product made from the purchased Biofene. Amyris expects total revenue from the five-year agreement to be more than $100 million. In year-five of the supply agreement term, the agreement is projected to generate approximately $40 million of annual revenue, which Amyris expects will be renewed at that level in subsequent years. Due to the competitive nature of this market, both parties have agreed to keep the targeted product and the customer’s name confidential. “This agreement represents a new highly disruptive partner application for our flexible Biofene ingredient ─ which supports multiple broad-based market applications and further solidifies Amyris’s track record of helping solve partners’ supply and product margin needs by supplying cost-advantaged renewable ingredients that perform better than current supply sources,” said John Melo, President & CEO of Amyris. “We are experiencing significant growth in demand for our Biofene and Biofene-derivative applications from large markets such as tires, industrial lubricants,... read more

Amyris Named Gold 2016 Edison Award Winner — One of Highest Accolades for Innovation in Business

Recognized in Diagnostics & Disease Treatment Category Showcasing BioPharma Collaborative Excellence EMERYVILLE, Calif., April 25, 2016 (GLOBE NEWSWIRE) — Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, is pleased to announce it has been named a Gold Edison Award winner for its collaborative development work on production of artemisinin for life-saving artemisinin combination therapies (ACTs), the World Health Organization’s recommended first-line treatment for malaria. The Edison Awards, named after inventor Thomas Edison, are among the most prestigious accolades a company can receive and honor new product and service development, marketing, human-centered design and innovation that are considered “game-changing.” “Amyris is honored to be among the globally recognized business leaders to have received this prestigious award, which highlights our collaborative excellence in harnessing our advanced technology platform and innovation to help solve global problems,” said John Melo, Amyris President & CEO. “This showcases the hard work of our world-class scientists and the success in working with our partners.” Continued Melo, “We are applying our platform beyond the development of artemisinin, and expect our platform to support and accelerate drug discovery for companies in the biopharma space where we are in active discussions with several potential partners.” Advantaged Platform for Pharmaceutical Development Amyris’s advanced synthetic biology platform combines high-speed genomic engineering with high-performance screening and production scale-up, which provides a powerful alternative to support development and production of pharmaceutical precursors or ingredients such as artemisinic acid. By encoding microbes to efficiently produce molecules, Amyris has shown that its technology can help partners achieve cost-effective manufacturing of pure, high-quality ingredients very quickly. Amyris’s ability to manufacture natural and natural-like products also means that... read more

Amyris Creates Program to Reduce the Cost and Increase Access to Leading Malaria Treatment

EMERYVILLE, Calif., April 11, 2016 (GLOBE NEWSWIRE) — Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced the signing of a stock purchase agreement for a $5-million equity investment from the Bill & Melinda Gates Foundation. The investment is to fund a program to further reduce the cost of one of the world’s leading malaria treatments so that no child has to go without treatment for malaria. The program will focus on the continued production of high-quality and secure supplies of artemisinic acid and amorphadiene to be converted to artemisinin for use in artemisinin combination therapies (“ACTs”). ACTs are recommended by the World Health Organization (“WHO”) as the primary first-line treatment for malaria. “We are very pleased with the Gates Foundation’s commitment to eradicating Malaria and are happy to be a part of this effort,” said John Melo, Amyris President & CEO. “We believe in a world where no child should go untreated and that no parent should have to make a choice between treating their child or feeding their family. Lower cost and sustainably-produced artemisinin is a key part of the spectrum of solutions that can help eradicate this disease from our planet.” Continued Melo, “It is only through the work of public-private partnerships that these solutions can occur. With an advanced and proven platform, Amyris’s technology can, among other things, be used to accelerate drug discovery cost effectively while improving the global supply of important pharmaceuticals. And, we believe it is also poised to help leading pharmaceutical companies respond rapidly to pandemic crises, making the world a safer place for all of us.” Amyris’s founding purpose was... read more

Amyris Brotas Plant Sold Out for 2017-2020 Farnesene Volume ─ Project for Dedicated Flavors & Fragrances Initiated

EMERYVILLE, Calif., March 21, 2016 (GLOBE NEWSWIRE) — Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced an expansion project to add a dedicated flavors & fragrances manufacturing unit to its Brotas industrial fermentation complex in Brazil. This planned expansion enables the company to meet demand for contracted flavors and fragrances molecules for its collaboration partners. The expansion provides for focused use of the current Brotas industrial fermentation capacity to supply Amyris’s current partners and collaborators based on projected demand for Biofene® (Amyris-branded farnesene) serving the polymers, nutraceuticals and solvents markets through 2020. Expected demand will require new farnesene manufacturing capacity beyond the company’s current capacity at its Brotas plant. Amyris is in active discussions with current collaborators and partners to provide financing for the project, with construction expected to start in the second half of 2016. “After several years of application and product development activities in collaboration with our strategic partners, we’ve now transitioned to the commercialization phase of many applications,” said John Melo, Amyris President & CEO. “We are very fortunate that many of our partnerships are focused on solving supply chain challenges by replacing current raw material sources with lower-cost, better-performing, sustainably sourced material. This is enabling us to grow our supply of farnesene into these markets at a faster rate than we expected.” Continued Melo, “We expect to have five or more high performance fragrance molecules scaled as we complete 2016 and this, combined with strong farnesene demand, has enabled us to initiate a project for a dedicated flavors & fragrances operation at Brotas. We are very excited for our Brazilian operation as this will... read more

Amyris Biossance™ Brand Launches The Refresher ─ Luxurious, Quick & Effective Biodegradable Makeup Removing Cloths

  EMERYVILLE, Calif, March 17, 2016 (GLOBE NEWSWIRE) — Biossance™, the pioneer of sustainable solutions in beauty from Amyris, Inc. (Nasdaq:AMRS), announced today the latest new product in the Biossance skin care brand line ─ The Refresher Makeup Removing Cloths ─ marking the fourth product announced since brand launch in June 2015. Now available at biossance.com and HSN (hsn.com), The Refresher is a package of biodegradable cleansing cloths enriched with an all-natural antioxidant blend of ingredients that gently remove makeup and impurities without leaving skin tight or dry. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/13238941-ffca-41f1-a962-2d570dc4b34c   Moisturizing Cleansing and Biodegradable ─ Safe on Your Skin and Safe for the Planet The Refresher cloths are infused with the unique moisturizing power of Amyris’s squalane for ultimate smoothness and hydration along with hemisqualane for gentle yet effective cleansing and makeup-removing properties. And, each cloth is generously enriched with a unique antioxidant blend composed of rice bran, rosemary leaf and sunflower extracts, and vitamin E providing powerful antioxidant protection while naturally soothing the skin and delivering a beautiful radiant glow. They are suitable for all skin types, contain carefully selected ingredients, and are biodegradable so they’re safe on your skin and safe for the planet. Clinical validation tests conducted for The Refresher have found that 100% of women using the product agreed it is gentle to use around the eye area and does not leave skin feeling tight or dry and 95% agreed the product removes makeup in just a few strokes. *Ideal for all skin types *Dermatologist tested *Ophthalmologist tested *No parabens *No synthetic fragrance *Non-toxic *No phthalates *No... read more

Join our Mailing List

Sign Up